Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. MINI-PLUS verified major depressive episode (unipolar or bipolar).~2. ECT within the last 3 weeks.~3. Either Remission defined as MADRS \< 10 or~4. Response defined as MADRS \< 15 combined with patient assessed CGI-I of at least much improved~Exclusion Criteria:~1. Schizophrenia or Schizoaffective disorder~2. Addiction or Dependence~3. Kidney disease that contraindicates lithium treatment~4. Vascular or heart disease that contraindicates venlafaxine treatment~5. Uncontrolled Epilepsia~6. Age less that 18~7. Pregnancy or Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECT+pharmacotherapy (Type: EXPERIMENTAL): Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
- pharmacotherapy (Type: ACTIVE_COMPARATOR): Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).